MedTrace Logo

A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

NCT01226732 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-03-08

Study results available
· View outcomes & findings →

Summary

The investigators propose this Phase I trial of the combination of AUY922 and capecitabine to determine the maximum tolerated dose (MTD) in patients with advanced solid tumors. This combination treatment has potential applicability in tumor types where capecitabine or fluorouracil is a treatment option, including colorectal and breast cancer.

Conditions

  • Metastatic or Unresectable Solid Tumor Malignancy

Interventions

DRUG

Capecitabine

Taken orally twice daily on Days 1 through 14 of 21 day cycle.

DRUG

Hsp90 Inhibitor AUY 922

IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle

Sponsors & Collaborators

Principal Investigators

  • Johanna C Bendell, MD · SCRI Development Innovations, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-07-31
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01226732 on ClinicalTrials.gov